Table 2.
Hazard ratios for cardiovascular events
| All (n = 138) |
Patients without any cardiovascular events between two admissions (n = 107) |
Patients without a history of cardiovascular events before admission 1 (n = 98) |
||||
|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| Combined cardiovascular events | ||||||
| Unadjusted | 0.49 (0.29–0.83) | 0.009 | 0.39 (0.18–0.84) | 0.02 | 0.53 (0.26–1.09) | 0.08 |
| Model 1 | 0.44 (0.26–0.76) | 0.003 | 0.34 (0.16–0.75) | 0.01 | 0.43 (0.21–0.90) | 0.03 |
| Model 2 | 0.51 (0.29–0.88) | 0.02 | 0.39 (0.18–0.88) | 0.02 | 0.43 (0.20–0.94) | 0.03 |
| Model 3 | 0.50 (0.28–0.87) | 0.02 | 0.37 (0.16–0.86) | 0.02 | 0.41 (0.19–0.90) | 0.03 |
| Heart disease | ||||||
| Unadjusted | 0.67 (0.36–1.23) | 0.19 | 0.57 (0.25–1.32) | 0.19 | 0.90 (0.36–2.21) | 0.81 |
| Model 1 | 0.65 (0.35–1.19) | 0.16 | 0.54 (0.23–1.27) | 0.16 | 0.85 (0.34–2.11) | 0.85 |
| Model 2 | 0.75 (0.40–1.41) | 0.37 | 0.65 (0.27–1.56) | 0.33 | 0.77 (0.29–1.99) | 0.58 |
| Model 3 | 0.76 (0.40–1.43) | 0.39 | 0.64 (0.25–1.61) | 0.34 | 0.76 (0.29–2.01) | 0.59 |
| Stroke | ||||||
| Unadjusted | 0.47 (0.18–1.21) | 0.12 | NA | NA | 0.61 (0.17–2.15) | 0.44 |
| Model 1 | 0.41 (0.16–1.08) | 0.07 | NA | NA | 0.41 (0.11–1.53) | 0.19 |
| Model 2 | 0.55 (0.20–1.53) | 0.25 | NA | NA | 0.45 (0.11–1.82) | 0.26 |
| Model 3 | 0.54 (0.20–1.49) | 0.24 | NA | NA | 0.31 (0.07–1.31) | 0.11 |
| Death | ||||||
| Unadjusted | 0.48 (0.20–1.19) | 0.11 | 0.47 (0.16–1.40) | 0.17 | 0.61 (0.16–2.28) | 0.46 |
| Model 1 | 0.32 (0.12–0.84) | 0.02 | 0.32 (0.09–1.10) | 0.07 | 0.36 (0.08–1.50) | 0.16 |
| Model 2 | 0.35 (0.13–0.92) | 0.03 | 0.33 (0.09–1.17) | 0.09 | 0.36 (0.08–1.64) | 0.19 |
| Model 3 | 0.35 (0.13–0.93) | 0.04 | 0.31 (0.08–1.14) | 0.08 | 0.27 (0.06–1.24) | 0.09 |
NA = not applicable (the number of cases is below 10)
HRs = hazard ratios, CI = confidence interval
HRs and 95% CI for the outcomes in the continuous low MG-H1 group compared with those of others
Model 1 includes adjustments for the following potential confounders: age, sex, and current smoking
Model 2 includes adjustments for the potential confounders of model 1 plus dyslipidemia, hypertension, diabetes duration, and obesity
Model 3 includes adjustments for the potential confounders of models 1 and 2 plus glycated hemoglobin and eGFR.